CTRI/2010/091/002959尚未招募3 期
Phase III randomized controlled trial of Image Guided Intensity Modulated Radiotherapy (IG-IMRT) and Conventional Radiotherapy for late toxicity reduction reduction after postoperative radiotherapy in carcinoma cervix.
il0 个研究点目标入组 240 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Histopathological diagnosis of carcinoma cervix with postoperative intermediate or high risk features.
- •2.Age > 18 years
- •3.Planned for Wertheim's hysterectomy or has already undergone simple hysterectomy and has no evidence of residual pelvic nodes on MRI/PET imaging +/_ confirmatory nodal biopsy.
- •4.No evidence of paraaortic nodal biopsy.
- •5.WIlling for specimen archiving in tumor tissue biorepository.
排除标准
- •1.History of multiple previous abdominal surgeries placing patient at baseline high risk of bowel toxicity or any other medical condition with baseline bowel movement disorder.
- •2.Rectal Polyps or extensive hemorroids causing bleeding.
研究者
相似试验
招募中
3 期
A clinical trial to compare toxicity reduction between image guided intensity modulated radiotherapy (IG-IMRT) and conventional radiotherapy in Cancer Cervix (PARCER) patients.CTRI/2012/12/003249Tata Memorial Centre240
已完成
不适用
Phase I/II clinical trial of stereotactic body radiotherapy in patients with cervical cancer who are unsuitable for intracavitary brachytherapyterine cervical cancerJPRN-UMIN000036845Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital21
进行中(未招募)
不适用
The Positive Choices trial of a social marketing intervention to promote sexual health and reduce health inequalities among English secondary school studentsSexual healthISRCTN16723909ondon School of Hygiene & Tropical Medicine6,970
进行中(未招募)
1 期
Phase III randomized, placebo controlled study of sorafenib in repeated cycles of 21 days in combination with paclitaxel/carboplatin chemotherapy in subjects with unresectable stage III or stage IV melanomaunresectable, advanced Stage III or Stage IV melanomaEUCTR2005-000941-12-DEOnyx Pharmaceuticals, Inc.
进行中(未招募)
1 期
A randomised Phase III trial to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) versus 2-weekly CHOP alone in elderly patients with previously untreated systemic T- cell Lymphoma Short Title: A-CHOP-14 (elderly) - A-CHOP-14 (elderly)Primary therapy of patients with Alk-negative T-NHL in patients aged 61 - 80 yearsICD classification codes : ICD-O 9702/39717/39716/39708/39705/39714/3MedDRA version: 9.1Level: LLTClassification code 10002464Term: Angiomimmunoblastic (AILD, LgX (Kiel Classification)MedDRA version: 9.1Level: LLTClassification code 10025632Term: Malignant lymphomaEUCTR2007-000821-23-BEniversity Medicine Goettingen274
